Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • ROOMS:

Hidradenitis Suppurativa Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | InflaRx, Novartis, ChemoCentryx, AnaptysBio, AbbVie, UCB Biopharma

Hidradenitis Suppurativa Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | InflaRx, Novartis, ChemoCentryx, AnaptysBio, AbbVie, UCB Biopharma
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 24+ key pharma and biotech companies are working on 24+ pipeline drugs in the Hidradenitis Suppurativa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Hidradenitis Suppurativa Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Hidradenitis Suppurativa Market. 

The Hidradenitis Suppurativa Pipeline report embraces in-depth commercial, regulatory, and Hidradenitis Suppurativa clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Hidradenitis Suppurativa drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Hidradenitis Suppurativa Pipeline Analysis

Hidradenitis Suppurativa Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Hidradenitis Suppurativa treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Hidradenitis Suppurativa therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Hidradenitis Suppurativa companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Hidradenitis Suppurativa drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Hidradenitis Suppurativa therapeutic market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Hidradenitis Suppurativa Therapies by Phases

The report covers the emerging products under different phases of clinical development like -

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Hidradenitis Suppurativa Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

Hidradenitis Suppurativa Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Hidradenitis Suppurativa. Currently, InflaRx is leading the therapeutics market with its Hidradenitis Suppurativa drug candidates in the most advanced stage of clinical development.

Hidradenitis Suppurativa Companies Actively Working in the Therapeutic Market Include:

InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics, Novartis Pharmaceuticals, UCB Biopharma, Incyte Corporation, AbbVie, Aclaris Therapeutics, Boehringer Ingelheim, UNION Therapeutics, ACELYRIN, Priovant Therapeutics, MoonLake Immunotherapeutics, Eli Lilly, and many others.

Emerging and Marketed Hidradenitis Suppurativa Drugs Covered in the Report Include:

  • Vilobelimab: InflaRx

  • Secukinumab: Novartis

  • Avacopan: ChemoCentryx

  • Imsidolimab: AnaptysBio

  • Spesolimab: Boehringer Ingelheim

  • HUMIRA: AbbVie

  • COSENTYX (secukinumab): Novartis Pharmaceuticals

  • BIMZELX (bimekizumab): UCB Biopharma

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Hidradenitis Suppurativa Companies Working in the Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Hidradenitis Suppurativa Treatment Patterns

4. Hidradenitis Suppurativa - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Hidradenitis Suppurativa Late Stage Products (Phase-III)

7. Hidradenitis Suppurativa Mid-Stage Products (Phase-II)

8. Hidradenitis Suppurativa Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hidradenitis Suppurativa Discontinued Products

13. Hidradenitis Suppurativa Product Profiles

14. Major Hidradenitis Suppurativa Companies in the Market

15. Key Products in the Hidradenitis Suppurativa Therapeutics Segment

16. Dormant and Discontinued Products

17. Hidradenitis Suppurativa Unmet Needs

18. Hidradenitis Suppurativa Future Perspectives

19. Hidradenitis Suppurativa Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports By DelveInsight

Genital Herpes Market

"Genital Herpes Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Genital Herpes market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Genital Herpes market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Photography by Christophe Tomatis
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.